
New H3N2 Strain Blunts Flu Vaccine, U.S. Season Sees Weak Protection
This season’s U.S. flu vaccine performed poorly because a newly dominant H3N2 subclade (K) wasn’t well matched to the vaccine, leading to one of the lowest effectiveness rates in years (about 25%–30% in preventing illness severe enough to seek care; around 40% less likely for vaccinated children to need treatment). The winter surge was sharp (NYC called it the strongest in 20 years) with 16 states at times reporting high activity. CDC estimates roughly 27 million illnesses, 350,000 hospitalizations, and 22,000 deaths so far; about 101 pediatric deaths have occurred, most among unvaccinated or not-fully-vaccinated individuals. Adult vaccination is about 46.5%, and roughly 48% of kids were vaccinated as the season waned. Health officials say vaccines still curb severe illness and death, and WHO/FDA have advised updates to target subclade K for the next season.













